HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today the completion of an oversubscribed $102 million Series D financing. The round was led by Alpha Wave Ventures, a world leader in growth stage investments, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc.

爱迪生组织分解系统和新型组织分解治疗平台的制造商HistoSonics今天宣布，超额认购的1.02亿美元的D系列融资已经完成。本轮投资由成长期投资领域的全球领先企业Alpha Wave Ventures牵头，新投资者Amzak Health and HealthQuest Capital以及现有投资者Johnson&Johnson Innovation-JJDC，Inc.参与。

(JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board, and others.HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors.

（JJDC）、风险投资者、Lumira Ventures、Yonjin Venture、威斯康星州投资委员会等。HistoSonics是一家私营医疗器械公司，利用组织分解科学开发非侵入性平台和专有声束疗法，这是一种使用聚焦超声波机械破坏和液化不需要的组织和肿瘤的新型作用机制。

The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, brain, and others. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota.

该公司目前专注于在美国将爱迪生系统商业化，并选择全球肝脏治疗市场，同时将组织分解术的应用扩展到其他器官，如肾脏、胰腺、前列腺、大脑等。HistoSonics在密歇根州的安娜堡和明尼苏达州的明尼阿波利斯设有办事处。

The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition..

爱迪生系统用于肝肿瘤的非侵入性机械破坏，包括通过组织切片术部分或完全破坏不可切除的肝肿瘤。FDA尚未评估爱迪生系统治疗任何特定疾病或病症的效果。。